Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Market Cap	2.08T +12.4%
Revenue (ttm)	8.43B +6.9%
Net Income	-27.39B
EPS	-903.91
Shares Out	30.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,389
Open	73,000
Previous Close	73,600
Day's Range	67,600 - 74,900
52-Week Range	45,850 - 179,900
Beta	1.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 18
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2025, Mezzion Pharma's revenue was 7.91 billion, a decrease of -8.15% compared to the previous year's 8.61 billion. Losses were -34.93 billion, 79.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error